Deerfield Capital

Deerfield Management, established in 1994 and headquartered in New York, is a healthcare-focused investment management firm. It provides long-term structured investments in both public and private healthcare companies, spanning life science, medical device, diagnostic, digital health, and health service industries. The firm also offers information and investment services to foster a healthcare ecosystem.

Moses Adubi

Principal

Sumner Anderson

Partner, Public Structured Finance Group

Konstantinos Aprilakis

Partner, Therapeutics Team

Talia Askowitz

Principal, Healthcare Services team

Michael Bergen

Principal

Nicholas Bishop

Partner, Therapeutics Team

Brian Bizoza

Partner

Alexis Cazé

Partner and Co-COO

Alexis Cazé

Partner

Wenxi Chen

Principal

Brian Chow

Principal

James Flynn

President and Founder

Jordan Fogel

Principal

Jason Fuller

Partner

Howie Furst

Partner

Bharath Ganesan

Principal

Bharath Ganesan

Principal

Adam Greene

Partner

Jackson Harvey Ph.D

Analyst

Leslie Henshaw

Partner

Michael Hurley

Principal, Medical Technologies team

Jonathan David Isler

Partner, CFO

Terence Karnal

Partner

Avi Kometz

Partner

Timothy Leahy

Partner

Jonathan Leff

Partner

Gilan Megeed

Principal

Gilan Megeed

Principal

Vince Mellet

Partner

Vincent Mellet

Partner, Healthcare Services

Elliot Press JD

Partner

Jonathan Ramos

Principal

Veranika Razhkova

Principal

Bryan Sendrowski

Partner

William Slattery

Partner

Alison Stamas

Associate

Peter Steelman

Partner

Cameron Wheeler

Principal

Eddie Yang

Principal, Therapeutics Team

Brian Chow Ph.D

Principal

Past deals in Medical

The Oncology Institute of Hope and Innovation

Post in 2025
The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

BiomX

Post in 2025
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Perceive Pharma

Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Singular Genomics

Acquisition in 2024
Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Intus Care

Funding Round in 2024
Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.

Lomond Therapeutics

Venture Round in 2024
Lomond Therapeutics is a pharmaceutical firm that discovers and develops small molecule inhibitors that target escape variants in hematologic malignancies.

Day One Biopharmaceuticals

Post in 2024
Day One Biopharmaceuticals is a clinical-stage biotechnology company that specializes in developing targeted cancer therapies for patients of all ages, with a particular focus on pediatric patients. Recognizing the advancements in cancer research, the company aims to create treatments that can benefit both children and adults diagnosed with genetically defined cancers. Day One Biopharmaceuticals prioritizes the rapid development of therapies to meet the urgent needs of families facing cancer diagnoses. Their lead product candidate, DAY101, is an oral, highly-selective pan-RAF kinase inhibitor designed to penetrate the brain, addressing a significant treatment gap in pediatric oncology. By licensing and acquiring promising products from research institutions and other companies, Day One Biopharmaceuticals strives to bring effective medicines to market for those impacted by cancer.

Elion Therapeutics

Series B in 2024
Elion Therapeutics is a biotechnology company dedicated to addressing life-threatening invasive fungal infections (IFIs). The company develops innovative treatments by enhancing the existing Amphotericin B drug, aiming to provide a broad spectrum of antifungal options that are non-toxic to mammalian cells. Elion's approach is grounded in mechanistic insights, which facilitate the targeted optimization of natural compounds for improved therapeutic efficacy. Through its focus on clinical research and development, Elion seeks to deliver safer and more effective treatments for patients suffering from serious fungal infections.

R3 Vascular

Series B in 2024
R3 Vascular specializes in developing and manufacturing innovative medical devices aimed at treating peripheral arterial disease. The company focuses on bioresorbable scaffold technology, specifically creating vascular scaffolds that incorporate a sirolimus coating known for its anti-inflammatory properties. This technology is designed to balance strength and flexibility, enhancing treatment outcomes for patients. One of their notable products, the magnitude BRS device, is recognized as the thinnest bioresorbable scaffold tested in clinical settings, featuring a strut thickness of just 98 microns across various diameters. Through its proprietary polymer technologies, R3 Vascular aims to improve the management of peripheral arterial diseases, particularly in challenging areas such as below the knee.

BridgeBio Oncology Therapeutics

Venture Round in 2024
BridgeBio Oncology Therapeutics is a biopharmaceutical company specializing in the development of precision oncology therapeutics. It focuses on targeting RAS-dependent cancers, leveraging a profound understanding of RAS signaling biology to create drugs that selectively inhibit RAS-driven PI3K activation and a wide spectrum of KRAS mutants. The company aims to provide patients with tailored treatments that address both active and inactive cancer-driving states.

Lumeris

Venture Round in 2024
Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

BiomX

Post in 2024
BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Frontier Medicines

Series C in 2024
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

Reprieve Cardiovascular

Series A in 2024
Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

enGene

Post in 2024
enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Cogent Biosciences

Post in 2024
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Kura Oncology

Post in 2024
Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing targeted therapies for cancer treatment. The company’s primary product candidate, Tipifarnib, is an orally available farnesyl transferase inhibitor currently undergoing Phase II clinical trials for solid tumors, peripheral T-cell lymphomas, and various hematologic malignancies. In addition to Tipifarnib, Kura is advancing other small molecule candidates, including KO-947, which targets dysregulated extracellular signal-related kinases, and KO-539, aimed at inhibiting the menin-mixed lineage leukemia protein interaction. Kura Oncology emphasizes precision medicine, leveraging insights from cancer genomics to create targeted treatments for patients with specific genetic profiles, addressing significant unmet medical needs across various cancer types, including lung, colorectal, thyroid, pancreatic cancers, and blood cancers such as lymphoma and leukemia. The company was founded in 2014 and operates primarily within the United States.

Solid Biosciences

Post in 2024
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Adela

Series A in 2023
Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Valneva

Post in 2023
Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Octave

Series B in 2023
Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Presidio Medical

Series C in 2023
Presidio Medical, Inc. is a clinical-stage medical device company based in South San Francisco, California, that focuses on developing a neuromodulation technology platform aimed at treating chronic pain and other disorders affecting neuronal activity. Founded in 2017, the company is dedicated to creating a new class of therapeutic medical devices through its innovative bioelectronic medicine. This platform is designed to provide patients with effective remedies for conditions related to neural activity, positioning Presidio Medical at the forefront of advancements in medtech and bioengineering.

Bitterroot Bio

Series A in 2023
Bitterroot Bio is a biotechnology company focused on developing innovative immunotherapy-based treatments for cardiovascular disease. By harnessing the immune system's natural capabilities to combat illness, the company conducts research to understand the significant roles of immune cells and immune modulators in the onset and advancement of cardiovascular conditions. Through its commitment to advancing medical treatments, Bitterroot Bio aims to provide effective therapies that can transform cardiovascular disease management and improve patient outcomes.

Ray Therapeutics

Series A in 2023
Ray Therapeutics is a company focused on developing innovative optogenetic gene therapies aimed at treating patients with blinding diseases. By creating technology that enhances the understanding of rare retinal conditions, the company strives to empower healthcare professionals to effectively diagnose, cure, and manage inherited retinal diseases. Through its commitment to advancing optogenetics, Ray Therapeutics seeks to improve the quality of life for those affected by these debilitating conditions.

Cortica

Series D in 2023
Cortica Inc. is a company dedicated to providing neurological therapies for children facing autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers tailored treatment programs that are informed by a comprehensive understanding of each child's neurobiology and developmental profile. The company operates multiple centers across California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village. Cortica's services encompass a wide range of assessments and therapies, including diagnoses for autism, ADHD, and developmental delays. Treatment options available include gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and various therapeutic interventions such as ABA therapy, parent coaching, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company provides these services through in-home, in-clinic, and telehealth modalities.

Epic Sciences

Series G in 2023
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Abivax

Post in 2023
Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

IronMatt

Grant in 2023
IronMatt's mission is to build a network committed to providing assistance to reduce family hardship, and fund pediatric brain tumor research, and patient care.

Perceive Biotherapeutics

Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages novel protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By utilizing multiple therapeutic modalities, Perceive Biotherapeutics seeks to provide medical professionals with effective solutions for improving eye health and preventing vision loss.

FogPharma

Series D in 2022
FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Intus Care

Series A in 2022
Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.

COTA Healthcare

Series E in 2022
COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Sientra

Post in 2022
Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Innervace

Series A in 2022
Innervace is a regenerative therapy company based in Philadelphia, Pennsylvania, focused on developing implantable tissue-engineered brain pathways to address neurodegenerative disorders. The company specializes in creating anatomically inspired living scaffolds designed for brain pathway reconstruction. Its lead clinical product is a tissue-engineered nigrostriatal pathway, which aims to replicate the lost pathway in patients with Parkinson's disease. By concentrating on the reconstruction of brain pathways rather than merely alleviating symptoms temporarily, Innervace offers innovative solutions that aim to improve the quality of life for individuals affected by these conditions. Established in 2018, the company is dedicated to advancing its products from development to commercialization.

SpringWorks Therapeutics

Post in 2022
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Insilico Medicine

Series D in 2022
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Insilico Medicine

Series D in 2022
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Epic Sciences

Series F in 2022
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Acutus Medical

Post in 2022
Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Apertura Gene Therapy

Series A in 2022
Apertura Gene Therapy is a biotechnology company focused on developing innovative genetic medicines aimed at treating intractable diseases with limited treatment options. The company specializes in the engineering of adeno-associated virus (AAV) capsids that effectively bind to the human Transferrin Receptor 1 (TfR1), facilitating intravenous delivery of therapeutics through receptor-mediated transcytosis across the blood-brain barrier. This approach allows for broad penetration of the central nervous system. In addition to AAV capsids, Apertura also develops regulatory elements and therapeutic payloads to address challenges related to cellular access, gene expression, pre-existing immunity, and manufacturability. By collaborating with corporate and academic partners, Apertura is committed to advancing gene therapy and improving outcomes for patients suffering from debilitating diseases.

Valneva

Post in 2022
Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Aurion Biotechnologies

Venture Round in 2022
Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Vibliome

Series A in 2022
Vibliome Therapeutics, Inc. is a biotechnology company based in Bozeman, Montana, established in 2017. The company specializes in researching and developing non-hormonal birth control options for men, utilizing homeodomain-interacting protein kinase 4 (HIPK4). Additionally, Vibliome focuses on creating small molecule kinase inhibitors aimed at treating various cancers and inflammatory diseases. Their innovative approach involves a systematic methodology that enables the development of inhibitors with unique selectivity profiles, leveraging the extensive array of over 500 kinases present in the human genome. By analyzing the design of Type II inhibitors, Vibliome aims to lock kinase targets in an inactive conformation, facilitating the identification of unique similarities and differences between kinases, which supports the advancement of therapeutics for cancer and other chronic conditions.

ConcertoCare

Series B in 2022
ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

Hyperfine

Post in 2021
Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

The Oncology Institute of Hope and Innovation

Post in 2021
The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

Lark

Series D in 2021
Lark is a developer of a virtual chronic disease prevention and management platform that offers personalized support and counseling to users. Utilizing advanced artificial intelligence alongside human coaches and connected devices, Lark provides real-time, 24/7 assistance, helping individuals make healthier choices and manage chronic conditions effectively. The company has established CDC-recognized programs, including its Diabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program, which collectively serve 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in 11 peer-reviewed journals and analyst reports. Founded in 2011 by Julia Hu and Jeff Zira, Lark is headquartered in Mountain View, California.

DeepSight

Series A in 2021
DeepSight Technology is a health technology company focused on advancing diagnostic medical imaging. By leveraging proprietary sensing technology, the firm combines patented hardware, software, and artificial intelligence to significantly enhance image quality and increase the depth penetration of medical ultrasounds. This innovation aims to make diagnostic imaging safer, faster, more affordable, and more accessible, ultimately benefiting public health and well-being. DeepSight's advancements enable healthcare enterprises to utilize enhanced ultrasound capabilities, which can lead to improved diagnostic outcomes.

BioAtla

Post in 2021
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

ARS Pharmaceuticals

Series D in 2021
ARS Pharmaceuticals, Inc., established in 2015 and headquartered in San Diego, California, is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. The company has created a novel intranasal epinephrine spray known as neffy, designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy utilizes a proprietary formulation that includes an absorption enhancer called Intravail, enabling it to deliver epinephrine effectively and rapidly through the nasal mucosa. This unique technology provides a convenient, reliable, and easy-to-use alternative for individuals at risk of life-threatening allergic reactions due to food, medications, or insect stings.

PepGen

Venture Round in 2021
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

GeneDx Holding

Post in 2021
GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Frontier Medicines

Series B in 2021
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

Novocardia

Series A in 2021
Novocardia is focused on transforming the delivery of cardiovascular care to enhance patient outcomes for those suffering from heart and vascular diseases. The company operates a cardiovascular care delivery network that aims to improve the quality and value of care provided to patients. By equipping cardiologists with essential tools and fostering collaborative relationships with health plans and primary care providers, Novocardia facilitates the transition to value-based care. Its platform incorporates various capabilities, including quality and process improvement initiatives and technology-enabled care delivery, to ensure that patients receive comprehensive and effective treatment, ultimately helping them lead longer and healthier lives.

Adela

Series A in 2021
Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Synthekine

Series B in 2021
Synthekine Inc. is a biotechnology company focused on developing innovative cytokine therapies and immunotherapies for cancer and autoimmune disorders. Established in 2018 and located in Menlo Park, California, the company employs advanced platforms such as engineered partial agonists and orthogonal cell therapies. Its Synthekine Platform utilizes surrogate agonists instead of traditional mutant cytokines, allowing for the creation of therapeutics that enhance efficacy while minimizing side effects. The product pipeline includes STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy targeting CD-19, along with STK-012, which consists of partial agonists of IL-2. Synthekine aims to revolutionize treatment paradigms by harnessing the principles of cytokine partial agonism and immunological specificity, leading to novel immunotherapies that improve patient outcomes.

CareMax

Post in 2021
CareMax is a technology-enabled care platform focused on delivering value-based care and chronic disease management for seniors. The company operates a network of medical centers that provide a wide range of healthcare and social services. Additionally, CareMax has developed a proprietary software and services platform that offers data, analytics, and rules-based decision tools to assist physicians in their practice. This integrated approach aims to enhance the quality of care for seniors while managing their healthcare needs effectively across the United States.

ADC Therapeutics

Post in 2021
ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.

Singular Genomics

Convertible Note in 2021
Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Nuvalent

Series B in 2021
Nuvalent is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, specifically aimed at clinically validated kinase targets. With a strong foundation in structure-based design, Nuvalent creates small molecules that exhibit high selectivity, aiming to address issues of resistance and minimize side effects associated with conventional treatments. The company's pipeline includes lead programs such as NVL-520 for ROS1-positive non-small cell lung cancer (NSCLC) and NVL-655 for ALK-positive NSCLC, as well as several discovery-stage initiatives. All operations are conducted within the United States, where Nuvalent seeks to enhance treatment options for patients with significant unmet medical needs.

Jaguar Gene Therapy

Series B in 2021
Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.

GH Research

Series B in 2021
GH Research PLC is a clinical-stage biopharmaceutical company that aims to transform the treatment of psychiatric and neurological disorders. The company is primarily focused on developing novel and proprietary therapies based on 5-MeO-DMT, a compound known as Mebufotenin, to address the needs of patients suffering from Treatment-Resistant Depression (TRD). Through its innovative approach, GH Research seeks to provide new therapeutic options for individuals who have not responded to conventional treatments.

Crossover

Series D in 2021
Crossover Health, established in 2010, specializes in providing comprehensive workplace healthcare services for employers and their employees. Headquartered in Aliso Viejo, California, with health centers across the United States, the company offers a wide range of services including primary care, urgent care, chronic disease management, health coaching, physical therapy, and more. Crossover Health aims to deliver exceptional member experiences and advanced health management services, ultimately promoting a healthy and motivated workforce for its clients.

Xeris Biopharma Holdings

Post in 2021
Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Jaguar Gene Therapy

Series A in 2021
Jaguar Gene Therapy is a clinical-stage biotechnology company focused on advancing gene therapy solutions for patients with severe genetic diseases. The company aims to address significant unmet medical needs by developing therapies that target nonworking or absent genes, introducing healthy copies of these genes to restore their function. By accelerating the process of bringing innovative gene therapies from research to clinical application, Jaguar Gene Therapy seeks to improve patient outcomes and enhance the overall standard of care for those affected by genetic disorders.

Xilio Therapeutics

Series C in 2021
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Nuvalent

Series A in 2021
Nuvalent is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, specifically aimed at clinically validated kinase targets. With a strong foundation in structure-based design, Nuvalent creates small molecules that exhibit high selectivity, aiming to address issues of resistance and minimize side effects associated with conventional treatments. The company's pipeline includes lead programs such as NVL-520 for ROS1-positive non-small cell lung cancer (NSCLC) and NVL-655 for ALK-positive NSCLC, as well as several discovery-stage initiatives. All operations are conducted within the United States, where Nuvalent seeks to enhance treatment options for patients with significant unmet medical needs.

MIVI Neuroscience

Series B in 2021
MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, that specializes in developing and commercializing solutions for neurointerventional procedures. Founded in 2013, the company offers a range of innovative products designed to enhance patient outcomes by improving the safety and efficacy of treatments for ischemic stroke. Its product portfolio includes high flow tubing, diagnostic and guide catheters, and aspiration pumps, as well as embolic protection and clot retrieval devices. MIVI Neuroscience aims to reduce complications and procedure times, thereby expanding treatment options for healthcare professionals and their patients.

Werewolf Therapeutics

Series B in 2021
Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics that enhance the body’s immune response to cancer. Founded in 2017, the company utilizes its proprietary PREDATOR platform to engineer conditionally activated molecules, known as INDUKINE molecules. These therapeutics are designed to remain inactive in peripheral tissues but activate selectively within the tumor microenvironment, addressing the limitations of traditional proinflammatory immune therapies. By stimulating both adaptive and innate immunity, Werewolf Therapeutics aims to improve cancer treatment outcomes.

Terns Pharmaceuticals

Series C in 2021
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

FogPharma

Venture Round in 2021
FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Encodia

Series C in 2020
Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Neomorph

Series A in 2020
Neomorph, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing protein degradation solutions, particularly through innovative molecular glue degraders. These targeted protein degradation drugs leverage the body's cellular machinery to eliminate proteins associated with various diseases. Neomorph aims to address critical health challenges by focusing on "undruggable targets," which are proteins that have been difficult to treat with traditional medicines. Through its research and development efforts, Neomorph is committed to advancing a pipeline of projects that hold promise for improving patient outcomes in the medical field.

Cystetic Medicines

Funding Round in 2020
Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.

Octave

Series B in 2020
Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Bridge Medicines

Funding Round in 2020
Bridge Medicines LLC is a biotechnology company based in New York, established in 2016. It specializes in drug discovery and the development of innovative therapeutics for various human diseases, particularly in oncology and rare diseases. The company collaborates with prominent institutions such as Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine, as well as industry partners like Takeda Pharmaceutical Company. Bridge Medicines focuses on advancing technologies from academic research through to clinical development, with a notable emphasis on developing inhibitors for acute leukemias and small molecule inhibitors for hereditary angioedema and inflammatory disorders. The initiative aims to provide comprehensive support throughout the drug development process, from validating preclinical studies to advancing candidates into human clinical trials.

InCarda Therapeutics

Series C in 2020
InCarda Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, focused on developing innovative therapies for cardiovascular diseases. The company specializes in an inhaled drug delivery system aimed at treating acute paroxysmal atrial fibrillation, allowing patients to administer treatment quickly during the onset of symptoms. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic medication designed to provide rapid relief from arrhythmic events. This method allows for effective medication delivery directly to cardiac tissue, which enhances treatment efficacy and simplifies the management of atrial arrhythmias. InCarda Therapeutics has completed Phase 1 clinical trials and is progressing through Phase 2 with its lead product.

Curation Health

Series A in 2020
Curation Health, LLC is a clinical decision support company that provides a platform designed to enhance value-based care. Established in 2018 and based in Annapolis, Maryland, its platform integrates with electronic health records to deliver actionable risk adjustment insights. This functionality allows healthcare providers to capture accurate clinical opportunities before and after patient visits, ensuring precise documentation and improving performance in various healthcare programs, including Medicare advantage and Medicaid risk programs. By leveraging clinical and quality rules, Curation Health aims to simplify clinical data management and improve patient care, facilitating a seamless transition from fee-for-service to value-based care models.

Olema Oncology

Series C in 2020
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

Ready

Series C in 2020
Ready Responders, Inc. focuses on enhancing community health by providing immediate medical care and support for various health needs. Founded in 2016 and headquartered in New Orleans, Louisiana, the company offers services such as 911 quick responses, telehealth consultations, and patient access to emergency medical professionals. Their responders visit patients at home to address physical, mental, and social health needs, utilizing technology to connect with advanced medical providers. Ready Responders also facilitates connections to external resources for ongoing support and aims to improve patient experiences while reducing overall care costs. The company operates in multiple locations across Louisiana, Nevada, New York City, and the National Capital Region, and is in-network with many major insurance providers.

Reprieve Cardiovascular

Venture Round in 2020
Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

GeneDx Holding

Series C in 2020
GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

AdaptHealth

Private Equity Round in 2020
AdaptHealth is a provider of patient-centered healthcare-at-home solutions, specializing in home medical equipment (HME), medical supplies, and associated services. The company distributes a wide range of clinically driven products designed to support patients in living independently, including sleep and respiratory therapy equipment, mobility aids, wound care supplies, and nutrition services. AdaptHealth also offers vital services such as continuous glucose monitoring and insulin pumps for diabetes management, as well as oxygen and chronic therapy services. Founded in 2012 and headquartered in Phoenixville, Pennsylvania, the company serves patients and healthcare institutions across several states, including Pennsylvania, New Jersey, New York, Maryland, and Delaware. Additionally, AdaptHealth provides online bill payment services to assist patients in managing their medical equipment expenses.

Annexon Biosciences

Series D in 2020
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

Somatus

Series C in 2020
Somatus, Inc. is a healthcare company focused on providing specialized kidney care services aimed at delaying or preventing the progression of chronic kidney disease. Founded in 2016 and headquartered in McLean, Virginia, Somatus collaborates with health plans, health systems, nephrology, and primary care groups to deliver integrated care for patients with or at risk of kidney disease. Its comprehensive services include home hemodialysis, peritoneal dialysis, in-center hemodialysis, kidney transplant, and conservative care. By utilizing vertically integrated clinical services and technology, Somatus seeks to improve patient outcomes, enhance care coordination, and promote the use of home dialysis modalities while increasing the rates of kidney transplantation. The company's mission is to ensure that patients can access the care they need to manage kidney disease effectively.

Meditrina

Venture Round in 2020
Meditrina, Inc. is a medical device company based in San Jose, California, specializing in tissue removal solutions for intrauterine pathology. Founded in 2016, the company has developed the Aveta System, an all-in-one solution designed for hysteroscopic diagnostic and therapeutic procedures. This system enables healthcare professionals to perform tasks such as the removal of polyps and fibroids in both office and operating room settings. The Aveta System features wide-angle HD hysteroscopy with electronic image-lock, advanced fluid management for better pressure and fluid control, and a compact design that allows for seamless integration into various medical environments. By providing advanced, convenient, and cost-effective options, Meditrina aims to enhance the care experience for both patients and physicians.

ARTMS

Series A in 2020
ARTMS is a technology developer focused on transforming the production of diagnostic imaging isotopes. The company has created the QUANTM Irradiation System, which supports decentralized and local production of essential medical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. This innovative technology allows for cost-effective, high-yield production using local hospital-based medical cyclotrons, thereby enabling the nuclear medicine industry to better manage supply chain demands and enhance the availability of critical imaging agents. Through its advancements, ARTMS aims to improve access to important diagnostic tools in healthcare.

ADC Therapeutics

Post in 2020
ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.

Intersect ENT

Convertible Note in 2020
Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.

CorVent

Seed Round in 2020
CorVent Medical, Inc., established in 2020 and headquartered in New York, specializes in developing and manufacturing ventilators for critical care applications. Its flagship product, the RESPOND Ventilator, is a compact, single-use device designed to meet a wide range of patient respiratory needs. Weighing 15 pounds (7 kg), it is easy to deploy and has been tested to meet international ICU ventilation standards. The RESPOND Ventilator is designed for maintenance-free use, ensuring reliability and a long shelf life, thereby reducing total cost of ownership. Additionally, CorVent offers ventilator tubing connectors and accessories to complement its core product offerings.

LetsGetChecked

Series C in 2020
LetsGetChecked is a healthcare technology company that facilitates at-home health testing. It connects users with regulated laboratories worldwide for various tests, including general wellness, sexual health, women's health, men's health, and COVID-19. Users collect samples at home using provided kits and mail them back for analysis; results are then accessible online. The platform aims to empower individuals to proactively manage their health, offering services across the United States, Canada, and Europe.

Ready

Series B in 2020
Ready Responders, Inc. focuses on enhancing community health by providing immediate medical care and support for various health needs. Founded in 2016 and headquartered in New Orleans, Louisiana, the company offers services such as 911 quick responses, telehealth consultations, and patient access to emergency medical professionals. Their responders visit patients at home to address physical, mental, and social health needs, utilizing technology to connect with advanced medical providers. Ready Responders also facilitates connections to external resources for ongoing support and aims to improve patient experiences while reducing overall care costs. The company operates in multiple locations across Louisiana, Nevada, New York City, and the National Capital Region, and is in-network with many major insurance providers.

RubiconMD

Series C in 2020
RubiconMD, Inc. operates an online platform that facilitates communication between primary care clinicians and specialists through its eConsult service. This platform allows primary care providers to seek expert guidance on medical cases, thereby enhancing patient care and reducing healthcare costs. In addition to the eConsult service, RubiconMD offers a continuing medical education (CME) program for eConsult submissions, live and on-demand webinars, and RubiconRx, a clinical pharmacy platform that supports patient medication access. The company also provides support in electronic health records, workflow integration, onboarding, and clinician engagement. Founded in 2013 and headquartered in New York, RubiconMD serves a diverse clientele, including employers, community health centers, correctional health facilities, health plans, and direct primary care practices.

Element Science

Series C in 2020
Element Science, Inc. is a medical device and digital health company focused on developing solutions for high-risk cardiovascular patients. The company's flagship product is a patch-based wearable cardioverter defibrillator that continuously monitors heart activity to protect against sudden cardiac death. This device integrates advanced data science and machine learning algorithms with strict electromechanical medical device standards, creating a proprietary digital platform that enhances patient care as individuals transition from hospital to home. Founded in 2011 and headquartered in San Francisco, California, Element Science aims to address critical health needs and reduce hospitalization rates associated with heart disease. The company was previously known as Revive Defibrillation Systems, Inc. before adopting its current name in 2014.

Farapulse

Venture Round in 2020
Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.

Generation Bio

Series C in 2020
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Neomorph

Seed Round in 2020
Neomorph, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing protein degradation solutions, particularly through innovative molecular glue degraders. These targeted protein degradation drugs leverage the body's cellular machinery to eliminate proteins associated with various diseases. Neomorph aims to address critical health challenges by focusing on "undruggable targets," which are proteins that have been difficult to treat with traditional medicines. Through its research and development efforts, Neomorph is committed to advancing a pipeline of projects that hold promise for improving patient outcomes in the medical field.

Civetta Therapeutics

Series A in 2019
Civetta Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing small molecule therapeutics aimed at targeting beta-propeller proteins for the treatment of cancers and other diseases. Founded in 2018, Civetta specializes in leveraging its expertise across biochemistry, biology, and medicinal chemistry to advance new medicines. Beta-propeller proteins serve as structural scaffolds that facilitate protein-protein interactions and are involved in various biological processes, including the pathogenesis of cancer, neurodegeneration, and metabolic diseases. The company aims to build a diverse portfolio of therapeutics by integrating its knowledge in drug development, with a vision to establish itself as a leader in the therapeutic use of propeller domains.

Contessa

Series D in 2019
Contessa, based in Nashville, specializes in Home Recovery Care, a model designed to deliver inpatient hospital care directly in patients' homes. Founded in 2015, the company offers a comprehensive range of services, including acute care, post-acute care, and surgical procedures, supported by its proprietary health informatics platform. This innovative approach allows health systems to enhance their care delivery by treating patients outside of traditional hospital settings, ultimately leading to improved patient outcomes and experiences. Contessa's solutions provide significant cost savings for health plans, enabling a more efficient and effective healthcare model.

AdaptHealth

Post in 2019
AdaptHealth is a provider of patient-centered healthcare-at-home solutions, specializing in home medical equipment (HME), medical supplies, and associated services. The company distributes a wide range of clinically driven products designed to support patients in living independently, including sleep and respiratory therapy equipment, mobility aids, wound care supplies, and nutrition services. AdaptHealth also offers vital services such as continuous glucose monitoring and insulin pumps for diabetes management, as well as oxygen and chronic therapy services. Founded in 2012 and headquartered in Phoenixville, Pennsylvania, the company serves patients and healthcare institutions across several states, including Pennsylvania, New Jersey, New York, Maryland, and Delaware. Additionally, AdaptHealth provides online bill payment services to assist patients in managing their medical equipment expenses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.